CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven International Breast Cancer Study Group trials

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 701-708

  Keshaviah, A ^a   Dellapasqua, S ^b   Rotmensz, N ^b   Lindtner, J ^c   Crivellari, D ^d   Collins, J ^e   Colleoni, M ^b   Thurlimann B ^f,g   Mendiola, C ^h   Aebi, S ^g,i   Price, K N ^a,j   Pagani, O ^g,k   Simoncini, E ^l   Castiglione Gertsch, M ^m   Gelber, R D ^a,j,n   Coates, A S ^o   Goldhirsch, Aron ^b,k  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^l SPEDALI CIVILI   (Italy)

^m International Breast Cancer Study Group Coordinating Center   (Switzerland)

ⁿ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^o UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Alkaline phosphatase; Breast cancer; CA15 3; Tumor marker

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GOSERELIN; METHOTREXATE; MUCIN 1; TAMOXIFEN; TOREMIFENE;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL COOPERATION; LIVER CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; RECURRENCE RISK;

EID: 34047107850     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl492     Document Type: Article

References (40)

1. Gendler SJ, Spicer AP, Lalani EN et al. Structure and biology of a carcinoma-associated mucin, Muc1. Am Rev Respir Dis 1991; 144: S42-S47.
2. Hayes DF, Mesa-Tejada R, Papsidero L et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: A Cancer and Leukemia Group B study. J Clin Oncol 1991; 9: 1113-1123.
3. Bast RC Jr, Ravdin P, Hayes DF. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-1878.
4. National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. v.1.2007: Breast Cancer, 2006. http://www.nccn.org/ professionals/physician_gls/PDF/breast.pdf
5. Shering SG, Sherry F, McDermott EW et al. Preoperative CA15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998; 83 (12): 2521-2527.
6. Kurebayashi J. Biomarkers in breast cancer. Gan To Kagaku Ryoho 2004; 31 (7): 1021-1026.
7. Canizares F, Sola J, Perez M et al. Preoperative values of CA15-3 and CEA as prognostic factors in breast cancer: A multivariate analysis. Tumour Biol 2001; 22 (5): 273-281.
8. Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA15-3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002; 76 (2): 95-102.
9. Molina R, Filella X, Zanon G et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res 2003; 23 (2A): 1043-1050.
10. Gion M, Boracchi P, Dittadi R et al. Prognostic role of serum CA15-3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002; 38 (9): 1181-1188.
11. McLaughlin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumor marker CA15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000; 15 (4): 340-342.
12. Molina R, Jo J, Filella X et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999; 19 (4A): 2551-2555.
13. Hayes DF, Sekine H, Ohno T et al. Use of a mAb for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671-1677.
14. Perey L, Hayes DF, Kufe D. Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res 1992; 52: 6365-6370.
15. Perey L, Hayes DF, Maimonis P et al. Tumor-specific reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the D3 human breast carcinoma-associated antigen. Cancer Res 1992; 52: 2563-2568.
16. Brockhausen I, Yang JM, Burchell J et al. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 1995; 233 (2): 607-617.
17. Berruti A, Tampellini M, Torta M et al. Prognostic value in predicting overall survival of two mucinous markers: CA15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A (14): 2082-2084.
18. Hayes DF. Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res 1996; 140: 101-113.
19. Hayes DF. Tumor markers for breast cancer. Current utilities and future prospects. Hematol Oncol Clin North Am 1994; 8 (3): 485-506.
20. Hayes DF. Markers of increased risk for failure of adjuvant therapies. Breast 2003; 12 (6): 543-549.
21. Crivellari D, Price KN, Hagen M et al. Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG). Ann Oncol 1995; 6 (8): 769-776.
22. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003; 95: 1833-1846.
23. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node negative breast cancer: A randomized trial. J Natl Cancer Inst 2002; 94: 1054-1065.
24. International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 2001; 10 (Suppl 3): 130-138.
25. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: First results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004; 15: 1749-1759.
26. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93. J Clin Oncol 2006; 24: 1332-134.
27. International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: Results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24: 370-378.
28. Briasoulis E, Andreopoulou E, Tolis CF et al. G-CSF induces elevation of circulating CA15-3 in breast carcinoma patients treated in an adjuvant setting. Cancer 2001; 91 (5): 909-917.
29. Buamah PK, Bent DJ, Bodger WA, Skillen AW. A profile of serum CA15-3, carcinoembryonic antigen, alkaline phosphatase, and gamma-glutamyl transferase levels in patients with breast cancer. J Surg Oncol 1993; 53 (2): 84-87.
30. Basuyau JP, Brunelle P, Charrot P et al. CA15-3 and early diagnosis of recurrence in breast cancer. Bull Cancer 1993; 80 (3): 213-218.
31. Lauro S, Trasatti L, Bordin F et al. Comparison of CEA, MCA, CA15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999; 19 (4C): 3511-3515.
32. Kokko R, Holli K, Hakama M. CA15-3 in the follow-up of localized breast cancer: A prospective study. Eur J Cancer 2002; 38 (9): 1189-1193.
33. Ritzke C, Stieber P, Untch M et al. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. Anticancer Res 1998; 18 (2B): 1243-1249.
34. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542-1550.
35. Tomiak E, Piccart M. Routine follow-up of patients after primary therapy for early breast cancer: Changing concepts and challenges for the future. Ann Oncol 1993; 4 (3): 199-204.
36. Pandya KJ, McFadden ET, Kalish LA et al. A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group adjuvant chemotherapy trials for breast cancer. A preliminary report. Cancer 1985; 55 (1): 202-205.
37. The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. J Am Med Assoc 1994; 271 (20): 1587-1592.
38. Palli D, Russo A, Saieva C et al. Intensive vs Clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. J Am Med Assoc 1999; 281 (17): 1586.
39. Rosselli Del Turco M, Palli D et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. J Am Med Assoc 1994; 271 (20): 1593-1597.
40. Rojas MP, Telaro E, Russo A et al. Follow-up strategies for women treated for early breast cancer [Review]. Cochrane Database Syst Rev 2005; (1): CD001768.